teachey-davidPrinciple Investigator: Dr. David Teachey

Disease: Autoimmune lymphoproliferative syndrome, Evans disease, systemic lupus erythematosus, autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura, common variable immunodeficiency

Research Description: Children with autoimmune diseases that affect their blood cells require aggressive treatment with immunosuppressive drugs. These drugs are not very effective and have excessive side effects. Dr. Teachey previously investigated the use of sirolimus, a safe generic drug with few sides effects, to successfully treat autoimmune lymphoproliferative syndrome (ALPS). Based on these results. Dr. Teachey tested sirolimus in children with other autoimmune diseases. A total of 30 children were enrolled in the clinical trial, and sirolimus led to a response in 22 children. The results support sirolimus as a treatment option for children suffering from six types of autoimmune diseases. Sirolimus has the potential to improve quality of life and lower medical costs for many of these patients.

CWR funding role: Primary funder

Publication:  Blood 

Since publication

→ Data are supporting off-label clinical use

Sign up for our eNewsletter today!


First Name

Cures Within Reach


All funds donated to Cures Within Reach may be tax deductible for federal income tax purposes.  CWR is recognized by the IRS as a 501(c)3 tax-exempt not-for-profit organization, tax ID 20-3620169.


Friday the 20th. Copyright 2018 Cures Within Reach.